News

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

If waste DNA or RNA remains in cells, it can lead to diseases such as Alzheimer’s and autoimmune conditions. Writing in Nucleic Acids Research, scientists led by Oliver Daumke of the Max Delbrück Center describe the role one enzyme plays in removing this waste.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

When the PRDM16 gene mutates, heart muscle cells undergo changes in their metabolism. This increases the risk of congenital heart failure in women more than men, as a ECRC research team led by Sabine Klaassen and Jirko Kühnisch reports in “Cardiovascular Research.”

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

Internationally renowned for pioneering achievements and geared to inter-institutional cooperation: 22 research groups at the Berlin Institute for Medical Systems Biology in the Max Delbrück Center (MDC-BIMSB) explore how genes regulate life. It is now celebrating its 15th birthday.

The Max Delbrück Center has revised its guidelines for good scientific practice. Based on these guidelines, the institute commits its scientists to integrity and honesty in their research, exemplary leadership and training, as well as proper attribution of intellectual property.

The Max Delbrück Center in Berlin and Heidelberg University will found a new Helmholtz Institute for Translational AngioCardioScience (HI-TAC) in Mannheim and Heidelberg. The Helmholtz Senate voted in favor of the institute, which will integrate vascular biomedicine, systems biology and heart research.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.